Abstract
Background Accurately identifying COVID-19 episodes was crucial during the early pandemic for evaluating interventions. Results from diagnostic tools like PCR, rapid antigen test (RAT), and serology are affected by factors such as timing of tests and vaccination status. The BRACE trial, which investigated the impact of BCG vaccination on COVID-19 prevalence among healthcare workers, developed a comprehensive algorithm integrating these diagnostic tools for illness episode classification. Methods In the BRACE trial, 3988 participants reported 5512 febrile/respiratory illness episodes and provided longitudinal blood samples over one year. SARS-CoV-2 diagnosis relied on a three-component algorithm: (1) a serology algorithm assessing anti- SARS-CoV-2 nucleocapsid antibody seroconversion, (2) a PCR/RAT algorithm, and (3) an episode interpretation algorithm combining serology and PCR/RAT results to categorise episodes as COVID-19, Not COVID-19, or Missing. The component algorithms also accounted for vaccination status and timing of testing relative to symptom onset to refine episode classifications. Findings Of 5512 illness episodes, 890 (16%) were classified as COVID-19, 3852 (70%) as not COVID-19, and 770 (14%) as missing. Compared to relying solely on PCR/RAT results, integrating serology in the algorithm reduced the proportion of missing classifications by more than half. Among the COVID-19 episodes, 89% were identified by positive PCR/RAT results, and the remaining 11% (with missing or negative PCR/RAT tests) were identified by serology. Discordance between PCR/RAT and serology occurred in 12.8% of episodes. Interpretation An algorithm integrating PCR/RAT and serology results in the context of test timing and vaccine status enabled the accurate identification of COVID-19 episodes and minimised the number of episodes that would otherwise have been classified as missing.
Competing Interest Statement
This trial is financially supported by the Foundations listed in the Funding section; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. PR has received investigator-initiated research grants to his institution from Sanofi outside this work and has received institutional funding from GlaxoSmithKline and Sanofi for local and international lectures and from AstraZeneca, Clover Biopharmaceuticals, GlaxoSmithKline, Novavax, Sanofi, and Pfizer for participation in vaccine scientific advisory boards unrelated to this work. He has been an investigator in sponsored, multicentre vaccine trials for AstraZeneca, Moderna, Novavax, Pfizer, and Sanofi with funding to his institution. He is Chief investigator on an investigator led COVID-19 vaccine trial and institution has received funding from the Medical Research Future Fund. HSM has received investigator-initiated research grants to her institution from Sanofi and Pfizer outside this work. She has been an investigator in sponsored, multicentre vaccine trials for Iliad, Seqirus and Pfizer, with funding to her institution. She is a Chief investigator on an investigator led COVID-19 vaccine trial and institution has received funding from the Medical Research Future Fund.
Clinical Trial
NCT04327206
Clinical Protocols
https://bmjopen.bmj.com/content/11/10/e052101
Funding Statement
The BRACE trial is supported by the Bill & Melinda Gates Foundation [INV017302], the Minderoo Foundation [COV-001], Sarah and Lachlan Murdoch, the Royal Children's Hospital Foundation [2020-1263 BRACE Trial], Health Services Union NSW, the Peter Sowerby Foundation, SA Health, the Insurance Advisernet Foundation, the NAB Foundation, the Calvert-Jones Foundation, the Modara Pines Charitable Foundation, the UHG Foundation Pty Ltd, Epworth Healthcare and individual donors. The Murdoch Children's Research Institute (MCRI) leads the BRACE trial across 36 sites in five countries. It is supported by the Victorian Government's Operational Infrastructure Support Programme. NC is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (GNT1197117). LFP is supported by the Swiss National Science Foundation (Early Postdoc Mobility Grant, P2GEP3_178155).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee (No. 62586) at he Royal Children's Hospital Melbourne gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.